Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Latch Q4 Sales $14.50M Beat $13.56M Estimate

Latch (NASDAQ:LTCH) reported quarterly sales of $14.50 million which beat the analyst consensus estimate of $13.56 million by 6.93 percent.

byBill Haddad

February 24, 2022

1 minute read

Latch (NASDAQ:LTCH) reported quarterly sales of $14.50 million which beat the analyst consensus estimate of $13.56 million by 6.93 percent.

BTIG Maintains Buy on Intuitive Surgical, Raises Price Target to $316

By Benzinga Newsdesk

Today, 3:00 AM

BTIG analyst Ryan Zimmerman maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and raises the price target from $247 to $316.

ISRG

Baird Maintains Outperform on Verisk Analytics, Raises Price Target to $184

By Vick Meyer

Today, 3:00 AM

Baird maintains Verisk Analytics (NASDAQ:VRSK) with a Outperform and raises the price target from $165 to $184.

VRSK

News

Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

By Benzinga Newsdesk

Today, 3:00 AM

Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that the Company has

RZLT

Joe Caltabiano’s Cannabis SPAC Shuts Down, Gives Back Money

By Nina Zdinjak

Today, 3:00 AM

Former Cresco Labs (OTC: CRLBF) executive Joseph Caltabiano is closing his special purpose acquisition company (SPAC) Choice Consolidation Corp. (NEO:CDXX.UN.U) (OTCQX:

CDXXF

Latch Q4 Sales $14.50M Beat $13.56M Estimate

Related Posts

BTIG Maintains Buy on Intuitive Surgical, Raises Price Target to $316

Baird Maintains Outperform on Verisk Analytics, Raises Price Target to $184

Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Joe Caltabiano’s Cannabis SPAC Shuts Down, Gives Back Money